\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\:\\ large\\,\\ hard\\,\\ irregular\\ mass\\ in\\ left\\ testicle\\.\ \(0\)\
\-\ labs\\:\\ afp\\ 3\\ \\(normal\\)\\,\\ bhcg\\ 4\\ \\(normal\\)\\,\\ ldh\\ 352\\ \\(elevated\\)\ \(0\)\
\-\ left\\ testicle\\ was\\ removed\\.\\ \\ radiation\\ rx\\ pending\\.\\ \\ expect\\ yearly\\ sonography\\ to\\ monitor\\ for\\ developement\\ of\\ tumor\\ in\\ right\\ testicle\\.\ \(0\)\
\-\ 1\\.\\ large\\,\\ lobular\\ intratesticular\\ mass\\,\\ 2\\.5\\ cm\\ x\\ 4\\.3\\ cm\\,\\ heterogeneous\\,\\ predominately\\ hypoechoic\\ lesion\\ in\\ left\\ testicle\\.\ \(0\)\
\-\ 2\\.\\ bilateral\\ coarse\\ microlithiasis\\.\ \(0\)\
\-\ testicular\\ microlithiasis\ \(11\)\
\-\ seminoma\\,\\ classic\\ type\ \(0\)\
\-\ ddx\\:\\ mass\ \(0\)\
\-\ 1\\.\\ seminoma\\ \\(classic\\,\\ spermatocytic\\)\\ \ \(0\)\
\-\ 2\\.\\ nonseminomatous\\ germ\\ cell\\ tumor\\ \\(mixed\\ malignant\\ germ\\ cell\\,\\ embryonal\\ cell\\ carcinoma\\,\\ yolk\\ sac\\,\\ teratoma\\,\\ choriocarcinoma\\)\ \(0\)\
\-\ 3\\.\\ stromal\\ tumor\\ \\(leydig\\,\\ sertoli\\,\\ granulosa\\ cell\\,\\ mixed\\ undifferentiated\\ sex\\ cord\\)\ \(0\)\
\-\ 4\\.\\ mixed\\ germ\\ cell\\-stromal\\ \\(gonadoblastoma\\,\\ germ\\ cell\\-stromal\\-sex\\ cord\\)\ \(0\)\
\-\ 5\\.\\ metastatic\\ \\(lymphoma\\,\\ leukemia\\,\\ myeloma\\,\\ carcinoma\\)\ \(0\)\
\-\ 6\\.\\ other\\ rare\\ tumors\\ and\\ tumorous\\ conditions\\.\ \(0\)\
\-\ ddx\\:\\ testicular\\ calcifications\ \(0\)\
\-\ 1\\.\\ solitary\\,\\ postinflammatory\\ granulomatous\\,\\ vascular\\.\ \(0\)\
\-\ 2\\.\\ microlithiasis\ \(0\)\
\-\ 3\\.\\ \\"burned\\-out\\"\\ germ\\ cell\\ tumor\ \(0\)\
\-\ 4\\.\\ large\\ cell\\ calcifying\\ sertoli\\ cell\\ tumor\ \(0\)\
\-\ 5\\.\\ teratoma\ \(0\)\
\-\ 6\\.\\ mixed\\ germ\\ cell\\ tumor\ \(0\)\
\-\ 7\\.\\ sarcoid\ \(0\)\
\-\ 8\\.\\ tuberculosis\ \(0\)\
\-\ 9\\.\\ chronic\\ infarct\ \(0\)\
\-\ ddx\\ from\\ rumack\\,\\ diagnostic\\ ultrasound\\,\\ 3rd\\ ed\\.\ \(0\)\
\-\ 19yo\\ male\\ with\\ 8\\ month\\ history\\ of\\ slowly\\ enlarging\\ left\\ testicular\\ mass\\.\ \(1\)\
\-\ due\\ to\\ what\\ appeared\\ at\\ presentation\\ to\\ be\\ a\\ rather\\ advanced\\ tumor\\ state\\,\\ along\\ with\\ bilateral\\,\\ numerous\\,\\ large\\ microliths\\,\\ there\\ was\\ brief\\ discussion\\ as\\ to\\ if\\ both\\ testicles\\ should\\ be\\ removed\\ concurrently\\ due\\ to\\ risk\\ of\\ cancer\\ in\\ the\\ contralateral\\ testicle\\.\ \(0\)\
\-\ although\\,\\ the\\ general\\ impression\\ derived\\ from\\ the\\ literature\\ indicates\\ testicular\\ microlithiasis\\ increases\\ ones\\ chance\\ of\\ having\\ testicular\\ cancer\\,\\ there\\ is\\ no\\ good\\ data\\ as\\ to\\ the\\ actual\\ risk\\.\\ \\ there\\ is\\ also\\ little\\ prospective\\ data\\ on\\ the\\ risk\\ of\\ developing\\ a\\ future\\ cancer\\.\\ \\ given\\ the\\ lack\\ of\\ clear\\ risk\\,\\ the\\ complications\\ of\\ complete\\ surgical\\ castration\\,\\ and\\ the\\ very\\ high\\ cure\\ rates\\ for\\ testicular\\ cancers\\,\\ surgery\\ solely\\ to\\ the\\ affected\\ testicle\\ coupled\\ with\\ follow\\ up\\ was\\ deemed\\ to\\ be\\ sufficient\\.\ \(0\)\
\-\ in\\ an\\ otherwise\\ healthy\\ patient\\ with\\ microlithiasis\\,\\ the\\ most\\ common\\ follow\\ up\\ is\\ yearly\\ sonography\\.\\ \\ again\\,\\ given\\ the\\ uncertain\\ risk\\,\\ the\\ relatively\\ common\\ incidence\\ of\\ microlithiasis\\,\\ the\\ high\\ cure\\ rates\\ for\\ testicular\\ tumors\\,\\ and\\ the\\ possible\\ deleterious\\ psychologic\\ and\\ economic\\ burdens\\ of\\ patients\\ recieving\\ yearly\\ cancer\\ screening\\ sonography\\,\\ some\\ authors\\ recommend\\ yearly\\ physical\\ examination\\ and\\ routine\\ self\\ examination\\ only\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ microlithiasis\\:\\ 0\\.08541913598411591\ \(0\)\
\-\ testicular\\:\\ 0\\.07154524796238296\ \(0\)\
\-\ testicle\\:\\ 0\\.06650455123664446\ \(0\)\
\-\ germ\\:\\ 0\\.061833136633483346\ \(0\)\
\-\ yearly\\:\\ 0\\.053808820384550815\ \(0\)\
\-\ cell\\:\\ 0\\.04304411583368739\ \(0\)\
\-\ risk\\:\\ 0\\.036074669549639705\ \(0\)\
\-\ sonography\\:\\ 0\\.03550943220757433\ \(0\)\
\-\ mixed\\:\\ 0\\.03499229268941288\ \(0\)\
\-\ tumor\\:\\ 0\\.03250728697267058\ \(0\)\
\-\ ddx\\:\\ 0\\.03154862469064565\ \(0\)\
\-\ sertoli\\:\\ 0\\.030363325552319125\ \(0\)\
\-\ cure\\:\\ 0\\.029918989049734862\ \(0\)\
\-\ cancer\\:\\ 0\\.02619268311762019\ \(0\)\
\-\ \\,\\:\\ 0\\.025241031749863627\ \(0\)\
\-\ seminoma\\:\\ 0\\.02479725343822852\ \(0\)\
\-\ rates\\:\\ 0\\.023148581921941445\ \(0\)\
\-\ data\\:\\ 0\\.021565798051002668\ \(0\)\
\-\ spermatocytic\\:\\ 0\\.020548993995259904\ \(0\)\
\-\ cell\\-stromal\\-sex\\:\\ 0\\.020548993995259904\ \(0\)\
\-\ tumorous\\:\\ 0\\.020548993995259904\ \(0\)\
\-\ psychologic\\:\\ 0\\.020548993995259904\ \(0\)\
\-\ burdens\\:\\ 0\\.020548993995259904\ \(0\)\
\-\ recieving\\:\\ 0\\.020548993995259904\ \(0\)\
\-\ 6\\.\\:\\ 0\\.01935701319279455\ \(0\)\
\-\ 2\\.\\:\\ 0\\.019003105886715093\ \(0\)\
\-\ 352\\:\\ 0\\.018933266301646975\ \(0\)\
\-\ cell\\-stromal\\:\\ 0\\.018933266301646975\ \(0\)\
\-\ gonadoblastoma\\:\\ 0\\.018933266301646975\ \(0\)\
\-\ burned\\-out\\:\\ 0\\.018933266301646975\ \(0\)\
\-\ 19yo\\:\\ 0\\.018933266301646975\ \(0\)\
\-\ castration\\:\\ 0\\.018933266301646975\ \(0\)\
\-\ deleterious\\:\\ 0\\.018933266301646975\ \(0\)\
\-\ 1\\.\\:\\ 0\\.018665658505577627\ \(0\)\
\-\ teratoma\\:\\ 0\\.018625812859493992\ \(0\)\
\-\ developement\\:\\ 0\\.017988126189506733\ \(0\)\
\-\ postinflammatory\\:\\ 0\\.017988126189506733\ \(0\)\
\-\ microliths\\:\\ 0\\.017988126189506733\ \(0\)\
\-\ economic\\:\\ 0\\.017988126189506733\ \(0\)\
\-\ removed\\:\\ 0\\.017961183187443313\ \(0\)\
\-\ large\\:\\ 0\\.017422307056700045\ \(0\)\
\-\ 5\\.\\:\\ 0\\.017182376265936713\ \(0\)\
\-\ nonseminomatous\\:\\ 0\\.01679739046977249\ \(0\)\
\-\ granulosa\\:\\ 0\\.016372398495893805\ \(0\)\
\-\ calcifying\\:\\ 0\\.016372398495893805\ \(0\)\
\-\ concurrently\\:\\ 0\\.016372398495893805\ \(0\)\
\-\ rumack\\:\\ 0\\.016013072901890874\ \(0\)\
\-\ deemed\\:\\ 0\\.015701810914421122\ \(0\)\
\-\ 4\\.\\:\\ 0\\.015685221307229828\ \(0\)\
\-\ leydig\\:\\ 0\\.015427258383753563\ \(0\)\
\-\ ones\\:\\ 0\\.015427258383753563\ \(0\)\
\-\ solely\\:\\ 0\\.015427258383753563\ \(0\)\
\-\ classic\\:\\ 0\\.015264591509594742\ \(0\)\
\-\ cord\\:\\ 0\\.015138339954337535\ \(0\)\
\-\ tumors\\:\\ 0\\.014963712623172499\ \(0\)\
\-\ rx\\:\\ 0\\.01475667080228088\ \(0\)\
\-\ undifferentiated\\:\\ 0\\.01475667080228088\ \(0\)\
\-\ coupled\\:\\ 0\\.01475667080228088\ \(0\)\
\-\ choriocarcinoma\\:\\ 0\\.01457009106411413\ \(0\)\
\-\ derived\\:\\ 0\\.014397345208277948\ \(0\)\
\-\ actual\\:\\ 0\\.014397345208277948\ \(0\)\
\-\ intratesticular\\:\\ 0\\.014236522664019318\ \(0\)\
\-\ bhcg\\:\\ 0\\.014086083220808197\ \(0\)\
\-\ sex\\:\\ 0\\.013944767086037953\ \(0\)\
\-\ brief\\:\\ 0\\.013685499871328806\ \(0\)\
\-\ testicles\\:\\ 0\\.013685499871328806\ \(0\)\
\-\ given\\:\\ 0\\.013656943554854743\ \(0\)\
\-\ \\(\\:\\ 0\\.013470614941610453\ \(0\)\
\-\ embryonal\\:\\ 0\\.013452205096137704\ \(0\)\
\-\ authors\\:\\ 0\\.013343766831254504\ \(0\)\
\-\ self\\:\\ 0\\.013343766831254504\ \(0\)\
\-\ \\)\\:\\ 0\\.013306064188593102\ \(0\)\
\-\ expect\\:\\ 0\\.013240149669084728\ \(0\)\
\-\ recommend\\:\\ 0\\.013240149669084728\ \(0\)\
\-\ prospective\\:\\ 0\\.013140943108667954\ \(0\)\
\-\ 4\\.3\\:\\ 0\\.013045786944285076\ \(0\)\
\-\ yolk\\:\\ 0\\.013045786944285076\ \(0\)\
\-\ chance\\:\\ 0\\.013045786944285076\ \(0\)\
\-\ predominately\\:\\ 0\\.012781617514665021\ \(0\)\
\-\ follow\\:\\ 0\\.012658272596486872\ \(0\)\
\-\ uncertain\\:\\ 0\\.01254436181697285\ \(0\)\
\-\ ldh\\:\\ 0\\.01247035552719527\ \(0\)\
\-\ stromal\\:\\ 0\\.01239862671911426\ \(0\)\
\-\ sufficient\\:\\ 0\\.01239862671911426\ \(0\)\
\-\ examination\\:\\ 0\\.012384256575639\ \(0\)\
\-\ afp\\:\\ 0\\.01226146937640346\ \(0\)\
\-\ cancers\\:\\ 0\\.01200922325836096\ \(0\)\
\-\ coarse\\:\\ 0\\.01178162775821197\ \(0\)\
\-\ indicates\\:\\ 0\\.011728039137641578\ \(0\)\
\-\ 9\\.\\:\\ 0\\.011675654858266151\ \(0\)\
\-\ increases\\:\\ 0\\.011675654858266151\ \(0\)\
\-\ myeloma\\:\\ 0\\.011574290960970722\ \(0\)\
\-\ monitor\\:\\ 0\\.011338635676888276\ \(0\)\
\-\ carcinoma\\:\\ 0\\.011291038088652058\ \(0\)\
\-\ lobular\\:\\ 0\\.011250662884387468\ \(0\)\
\-\ state\\:\\ 0\\.011250662884387468\ \(0\)\
\-\ 8\\.\\:\\ 0\\.011124632065575636\ \(0\)\
\-\ mass\\:\\ 0\\.011081221510000601\ \(0\)\
\-\ future\\:\\ 0\\.011044244708766384\ \(0\)\
\-\ contralateral\\:\\ 0\\.011005067276793469\ \(0\)\
\-\ hard\\:\\ 0\\.010966537435415355\ \(0\)\
\-\ high\\:\\ 0\\.010902312639052754\ \(0\)\
\-\ appeared\\:\\ 0\\.010854627833582344\ \(0\)\
\-\ slowly\\:\\ 0\\.010818487538626714\ \(0\)\
\-\ little\\:\\ 0\\.010818487538626714\ \(0\)\
\-\ 2\\.5\\:\\ 0\\.010782899025501334\ \(0\)\
\-\ literature\\:\\ 0\\.010713311698812102\ \(0\)\
\-\ up\\:\\ 0\\.01071257413078892\ \(0\)\
\-\ cm\\:\\ 0\\.010685110106372894\ \(0\)\
\-\ impression\\:\\ 0\\.010645741682790534\ \(0\)\
\-\ due\\:\\ 0\\.010630662717728856\ \(0\)\
\-\ 7\\.\\:\\ 0\\.010612677265559867\ \(0\)\
\-\ \\:\\:\\ 0\\.010538692922989883\ \(0\)\
\-\ what\\:\\ 0\\.010516208230215218\ \(0\)\
\-\ common\\:\\ 0\\.010425488167628892\ \(0\)\
\-\ developing\\:\\ 0\\.010423573431498401\ \(0\)\
\-\ leukemia\\:\\ 0\\.01022074970891185\ \(0\)\
\-\ sarcoid\\:\\ 0\\.01022074970891185\ \(0\)\
\-\ advanced\\:\\ 0\\.01019316356055054\ \(0\)\
\-\ enlarging\\:\\ 0\\.010138951760633834\ \(0\)\
\-\ conditions\\:\\ 0\\.009909487721442104\ \(0\)\
\-\ solitary\\:\\ 0\\.009885332040706563\ \(0\)\
\-\ 3rd\\:\\ 0\\.009861424114908918\ \(0\)\
\-\ physical\\:\\ 0\\.009773917340705074\ \(0\)\
\-\ bilateral\\:\\ 0\\.00966814792221186\ \(0\)\
\-\ sac\\:\\ 0\\.009656619089754293\ \(0\)\
\-\ granulomatous\\:\\ 0\\.00961345114624092\ \(0\)\
\-\ again\\:\\ 0\\.009571068118074975\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.009488546143597315\ \(0\)\
\-\ rather\\:\\ 0\\.009468364179161151\ \(0\)\
\-\ discussion\\:\\ 0\\.009331781045673847\ \(0\)\
\-\ 3\\:\\ 0\\.009328557234063123\ \(0\)\
\-\ be\\:\\ 0\\.009215081981426078\ \(0\)\
\-\ having\\:\\ 0\\.009149578777959778\ \(0\)\
\-\ incidence\\:\\ 0\\.009132118004698337\ \(0\)\
\-\ hypoechoic\\:\\ 0\\.009080506988667537\ \(0\)\
\-\ lack\\:\\ 0\\.009063554169718633\ \(0\)\
\-\ healthy\\:\\ 0\\.008980591593721656\ \(0\)\
\-\ numerous\\:\\ 0\\.00893219534325912\ \(0\)\
\-\ left\\:\\ 0\\.008914734445435103\ \(0\)\
\-\ there\\:\\ 0\\.008893115779475446\ \(0\)\
\-\ infarct\\:\\ 0\\.008838316790490028\ \(0\)\
\-\ pending\\:\\ 0\\.00861893848846094\ \(0\)\
\-\ affected\\:\\ 0\\.00861893848846094\ \(0\)\
\-\ good\\:\\ 0\\.008523224067020907\ \(0\)\
\-\ relatively\\:\\ 0\\.008523224067020907\ \(0\)\
\-\ screening\\:\\ 0\\.008496583750415726\ \(0\)\
\-\ ed\\:\\ 0\\.008418442277132175\ \(0\)\
\-\ general\\:\\ 0\\.00839296658824595\ \(0\)\
\-\ routine\\:\\ 0\\.007987055231118876\ \(0\)\
\-\ to\\:\\ 0\\.007963974050218857\ \(0\)\
\-\ irregular\\:\\ 0\\.007944863991856363\ \(0\)\
\-\ diagnostic\\:\\ 0\\.007893176678349784\ \(0\)\
\-\ complications\\:\\ 0\\.007893176678349784\ \(0\)\
\-\ rare\\:\\ 0\\.007735082048189502\ \(0\)\
\-\ 8\\:\\ 0\\.007447826476105707\ \(0\)\
\-\ calcifications\\:\\ 0\\.007405976118025064\ \(0\)\
\-\ clear\\:\\ 0\\.007364863900108731\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.007324464234953393\ \(0\)\
\-\ very\\:\\ 0\\.0072302695068930745\ \(0\)\
\-\ malignant\\:\\ 0\\.007199698546338697\ \(0\)\
\-\ otherwise\\:\\ 0\\.007154580963697774\ \(0\)\
\-\ complete\\:\\ 0\\.007010200312321805\ \(0\)\
\-\ labs\\:\\ 0\\.006927678337844145\ \(0\)\
\-\ was\\:\\ 0\\.006911031623871936\ \(0\)\
\-\ presentation\\:\\ 0\\.006861073740072453\ \(0\)\
\-\ 3\\.\\:\\ 0\\.00681555760405764\ \(0\)\
\-\ elevated\\:\\ 0\\.006758313196641172\ \(0\)\
\-\ although\\:\\ 0\\.006727107880131943\ \(0\)\
\-\ type\\:\\ 0\\.006714741791018439\ \(0\)\
\-\ possible\\:\\ 0\\.0067085832608020325\ \(0\)\
\-\ along\\:\\ 0\\.006582876169833371\ \(0\)\
\-\ x\\:\\ 0\\.006571250198945168\ \(0\)\
\-\ radiation\\:\\ 0\\.006536716199446005\ \(0\)\
\-\ vascular\\:\\ 0\\.006531009948540085\ \(0\)\
\-\ should\\:\\ 0\\.0063501364612792545\ \(0\)\
\-\ normal\\:\\ 0\\.0062452795086205175\ \(0\)\
\-\ some\\:\\ 0\\.006048783808547224\ \(0\)\
\-\ as\\:\\ 0\\.006026002358480782\ \(0\)\
\-\ only\\:\\ 0\\.00598930456523295\ \(0\)\
\-\ month\\:\\ 0\\.005975791470397691\ \(0\)\
\-\ ultrasound\\:\\ 0\\.005909376655026348\ \(0\)\
\-\ from\\:\\ 0\\.005904129198854136\ \(0\)\
\-\ lymphoma\\:\\ 0\\.005692770709532601\ \(0\)\
\-\ chronic\\:\\ 0\\.0056106984450046615\ \(0\)\
\-\ 4\\:\\ 0\\.005550051061023416\ \(0\)\
\-\ if\\:\\ 0\\.005404996349139011\ \(0\)\
\-\ patients\\:\\ 0\\.005155185546307752\ \(0\)\
\-\ for\\:\\ 0\\.005098658382116889\ \(0\)\
\-\ both\\:\\ 0\\.005086713265002614\ \(0\)\
\-\ metastatic\\:\\ 0\\.005014241034070141\ \(0\)\
\-\ in\\:\\ 0\\.0049113896286743005\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.004895419668139433\ \(0\)\
\-\ surgery\\:\\ 0\\.004836827655851457\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.004801280890401499\ \(0\)\
\-\ most\\:\\ 0\\.004598683314051459\ \(0\)\
\-\ other\\:\\ 0\\.004591232048257456\ \(0\)\
\-\ the\\:\\ 0\\.004511631668649793\ \(0\)\
\-\ surgical\\:\\ 0\\.0041869971334532715\ \(0\)\
\-\ lesion\\:\\ 0\\.004057238289045349\ \(0\)\
\-\ is\\:\\ 0\\.0039321033453477315\ \(0\)\
\-\ also\\:\\ 0\\.003926852199697323\ \(0\)\
\-\ male\\:\\ 0\\.0036018777106934107\ \(0\)\
\-\ an\\:\\ 0\\.002754463553111258\ \(0\)\
\-\ history\\:\\ 0\\.0027510828384780498\ \(0\)\
\-\ at\\:\\ 0\\.0026987486079991445\ \(0\)\
\-\ of\\:\\ 0\\.0024441356810766804\ \(0\)\
\-\ right\\:\\ 0\\.0021017056156419967\ \(0\)\
\-\ and\\:\\ 0\\.002098007059816066\ \(0\)\
\-\ no\\:\\ 0\\.0020056973209878833\ \(0\)\
\-\ patient\\:\\ 0\\.001996717787683888\ \(0\)\
\-\ a\\:\\ 0\\.0018489501250284442\ \(0\)\
\-\ on\\:\\ 0\\.00168739163721545\ \(0\)\
\-\ \\.\\:\\ 0\\.0014067415236710644\ \(0\)\
\-\ with\\:\\ 0\\.0010909480288101606\ \(0\)\
